# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price t...
Oppenheimer analyst Hartaj Singh maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price targe...
JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target f...
Truist Securities analyst Joon Lee reiterates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target fr...
Barclays analyst Gena Wang downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Overweight to Equal-Weight and raises the pr...
Guggenheim analyst Debjit Chattopadhyay maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price targe...
Wall Street is experiencing a sharp decline on the last trading day of the week, with all indices in the red at noon in New Yor...
Vertex Pharmaceuticals reported Q2 revenues of $2.65B, near the $2.66B estimate, with an adjusted EPS loss of $(12.83), missing...
Cantor Fitzgerald analyst Olivia Brayer reiterates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and maintains $480...